Ibrutinib is a targeted cancer therapy that works by blocking a specific enzyme known as Bruton's tyrosine kinase (BTK). This enzyme is crucial for the survival and spread of certain cancer cells. By inhibiting BTK, Manufacturer of ibrutinib prevents cancer cells from growing and spreading, which helps slow down the progression of the disease. It is mainly used for treating blood-related cancers such as chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL).
The effectiveness of Ibrutinib has revolutionized the treatment of these cancers, offering new hope to patients who might otherwise have limited options.